AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35128740 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDUS-professional dementia training intervention
Number of subjects: 7
Study 35128740 — intervention group
Group type: COMPARATOR
Intervention: Implementation sessions
Number of subjects: 7
Study 33202108 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape pomace supplementation for 6 weeks
Number of subjects: 49
Study 33202108 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 49
Study 32557307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian analyses with noninformative priors
Number of subjects: 10521
Study 32557307 — intervention group
Group type: EXPERIMENTAL
Intervention: Early interim looks at study results
Number of subjects: 10521
Study 32557307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-defined threshold stopping rules
Number of subjects: 10521
Study 35742443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training with a high-protein diet (Group A)
Number of subjects: 76
Study 35742443 — intervention group
Group type: COMPARATOR
Intervention: Regular physical activities and regular diet (Group B)
Number of subjects: 76
Study 33840246 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tunneling technique
Number of subjects: 130
Study 33840246 — intervention group
Group type: COMPARATOR
Intervention: Normal technique
Number of subjects: 130
Study 32916239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurotus ostreatus
Number of subjects: 2
Study 32916239 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametes versicolor
Number of subjects: 2
Study 32916239 — intervention group
Group type: COMPARATOR
Intervention: Uninoculated control
Number of subjects: 2
Study 33865239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose prophylactic anticoagulation
Number of subjects: 600
Study 33865239 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose prophylactic anticoagulation
Number of subjects: 600
Study 33388289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital tirofiban administration
Number of subjects: 984
Study 33388289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 33057314 — intervention group
Group type: EXPERIMENTAL
Intervention: IV1 (single intravenous dose of 15 mg TXA/kg prior to skin incision)
Number of subjects: 400
Study 33057314 — intervention group
Group type: EXPERIMENTAL
Intervention: IV2 (two intravenous doses of 15 mg TXA/kg: prior to skin incision and 6 hours after the first dose)
Number of subjects: 400
Study 33057314 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB (combined IV1 and TOP regimens)
Number of subjects: 400
Study 33057314 — intervention group
Group type: COMPARATOR
Intervention: TOP (2 g TXA in 50 mL of saline irrigated topically at the end of the surgery)
Number of subjects: 400
Study 33086234 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC + DTG
Number of subjects: 406
Study 33086234 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC + DTG
Number of subjects: 406
Study 33086234 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 406
Study 32469184 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg once daily)
Number of subjects: 933
Study 32469184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 933
Study 32469184 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 933
Study 35538536 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop plus rotation
Number of subjects: 57
Study 35538536 — intervention group
Group type: COMPARATOR
Intervention: Rotation alone
Number of subjects: 57
Study 32286154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead limb during drop jumps from different heights
Number of subjects: 17
Study 32286154 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop height increase
Number of subjects: 17
Study 32286154 — intervention group
Group type: EXPERIMENTAL
Intervention: Preset time window for landings and takeoffs
Number of subjects: 17
Study 32286154 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal asymmetry
Number of subjects: 17
Study 35429481 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time subcutaneous apomorphine infusion (up to 5 mg/h)
Number of subjects: 46
Study 35429481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 35429481 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time subcutaneous apomorphine infusion
Number of subjects: 46
Study 33067919 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mindfulness-based intervention (MBI) - weekly 1-hour mindfulness training over 4 weeks
Number of subjects: 239
Study 33067919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study 32274958 — intervention group
Group type: EXPERIMENTAL
Intervention: Data‐Based Instruction (DBI)
Number of subjects: 31
Study 35616850 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin α1 (Tα1) treatment
Number of subjects: 120
Study 35616850 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 120
Study 33402326 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-guided self-help for 12 weeks
Number of subjects: 34
Study 33402326 — intervention group
Group type: COMPARATOR
Intervention: Waiting list for telephone-guided self-help with no additional intervention for 12 weeks
Number of subjects: 34
Study 33300301 — intervention group
Group type: EXPERIMENTAL
Intervention: One cup of espresso coffee/day
Number of subjects: 21
Study 33300301 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cups of espresso coffee/day
Number of subjects: 21
Study 33300301 — intervention group
Group type: EXPERIMENTAL
Intervention: One cup of espresso coffee/day and two cocoa‐based products containing coffee two times per day
Number of subjects: 21
Study 33300301 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 33027160 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty (n = 1441)
Number of subjects: 2175
Study 33027160 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation (n = 734)
Number of subjects: 2175
Study 35300599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated treatment model for HFS and BEB using botulinum toxin type A (BoNT/A) with self-determined treatment schedule for 9 months.
Number of subjects: 130
Study 35300599 — intervention group
Group type: COMPARATOR
Intervention: Usual care appointments scheduled by treating clinicians.
Number of subjects: 130
Study 35300599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated treatment model for HFS and BEB.
Number of subjects: 130
Study 34293628 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 228
Study 34293628 — intervention group
Group type: COMPARATOR
Intervention: Triclofos
Number of subjects: 228
Study 33633036 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF (once-daily)
Number of subjects: 656
Study 32493995 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-style diet adherence (measured by DASH scores)
Number of subjects: 898
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on demographic, clinical, laboratory, comorbidities and ventilation variables ascertained at first 24 h of ICU admission and invasive ventilation.
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (OR, 1.02; 95% CI: 1.01‐1.03)
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean of respiratory rate (OR, 1.04; 95% CI: 1.01‐1.08)
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum of INR (OR, 1.14; 95% CI: 1.03‐1.31)
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolo‐arterial oxygen difference (OR, 1.002; 95% CI: 1.001‐1.003)
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum of RDW (OR, 1.17; 95% CI: 1.09‐1.27)
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean of temperature (OR, 0.70; 95% CI: 0.57‐0.86)
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum of lactate (OR, 1.15; 95% CI: 1.09‐1.22)
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum of blood urea nitrogen (OR, 1.02; 95% CI: 1.01‐1.03)
Number of subjects: 1075
Study 35820835 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell counts (OR, 1.03; 95% CI: 1.01‐1.06)
Number of subjects: 1075
Study 33894831 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 33894831 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 0
Study 32282531 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned submaximal load (Group A)
Number of subjects: 67
Study 32282531 — intervention group
Group type: COMPARATOR
Intervention: Perceived 50% effort (Group B)
Number of subjects: 67
Study 32037783 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic combined training (FiO2 21%)
Number of subjects: 14
Study 32037783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic combined training (FiO2 15%)
Number of subjects: 14
Study 36481265 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200mg testosterone enanthate per week in sesame oil)
Number of subjects: 50
Study 36481265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sesame seed oil only)
Number of subjects: 50
Study 34444797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 20
Study 34444797 — intervention group
Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 20
Study 32805700 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian-adjusted LED-based lighting (CaLED)
Number of subjects: 0
Study 32805700 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35014061 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 2433334 (25/50/100 mg once daily)
Number of subjects: 96
Study 35014061 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 2433334 (25 mg twice daily)
Number of subjects: 96
Study 35014061 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 2433334 (75 mg once daily)
Number of subjects: 96
Study 35014061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 32852548 — intervention group
Group type: EXPERIMENTAL
Intervention: MCL control with unannounced exercise (CLNA)
Number of subjects: 10
Study 32852548 — intervention group
Group type: EXPERIMENTAL
Intervention: MCL control with announced exercise (CLA)
Number of subjects: 10
Study 32852548 — intervention group
Group type: COMPARATOR
Intervention: Open-loop therapy (OL)
Number of subjects: 10
Study 36910347 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (40mg, 2 ml intravenous)
Number of subjects: 246
Study 36910347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml Vitamin B complex)
Number of subjects: 246
Study 34514890 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Focused Emotion-Regulation Therapy (GET)
Number of subjects: 44
Study 34514890 — intervention group
Group type: COMPARATOR
Intervention: Individual Supportive Therapy (ISP)
Number of subjects: 44
Study 34654636 — intervention group
Group type: EXPERIMENTAL
Intervention: Online nursing consultation through the Internet platform Red Sinapsis (RS)
Number of subjects: 80
Study 34654636 — intervention group
Group type: COMPARATOR
Intervention: Standard follow‐up at the clinic (Control Group)
Number of subjects: 80
Study 33980033 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin Type A (BTX‐A) injection
Number of subjects: 20
Study 33980033 — intervention group
Group type: COMPARATOR
Intervention: Counseling and self‐care and Michigan‐type occlusal splint (MOS)
Number of subjects: 20
Study 32521977 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster R‐CNN artificial intelligence approach
Number of subjects: 350
Study 32521977 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 350
Study 33293481 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Bilirubin (DB) level
Number of subjects: 983
Study 33293481 — intervention group
Group type: EXPERIMENTAL
Intervention: DB-MELD score
Number of subjects: 983
Study 33293481 — intervention group
Group type: EXPERIMENTAL
Intervention: DiBIC score
Number of subjects: 983
Study 33221195 — intervention group
Group type: EXPERIMENTAL
Intervention: OTL38 (0.025mg/kg) preoperatively during lung inspection
Number of subjects: 92
Study 33221195 — intervention group
Group type: EXPERIMENTAL
Intervention: OTL38 (0.025mg/kg) preoperatively during tumor resection
Number of subjects: 92
Study 33221195 — intervention group
Group type: EXPERIMENTAL
Intervention: OTL38 (0.025mg/kg) preoperatively during margin check
Number of subjects: 92
Study 33221195 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall benefit of IMI
Number of subjects: 92
Study 33618395 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stage periarticular injection
Number of subjects: 84
Study 33618395 — intervention group
Group type: COMPARATOR
Intervention: Late stage periarticular injection
Number of subjects: 84
Study 33200439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education (OHE), toothbrushes, fluoride toothpaste, and fluoride varnish on up to six occasions
Number of subjects: 4
Study 33200439 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish placement by medical professionals
Number of subjects: 4
Study 36360757 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (4-month daily micronutrient packets)
Number of subjects: 45
Study 36360757 — intervention group
Group type: COMPARATOR
Intervention: Control (no micronutrient supplementation)
Number of subjects: 45
Study 33755846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor administration (phenylephrine and noradrenaline)
Number of subjects: 133
Study 33755846 — intervention group
Group type: COMPARATOR
Intervention: Fluid challenges
Number of subjects: 133
Study 33755846 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GALA values between young and old patients
Number of subjects: 133
Study 32940745 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary multimodal assessment by pain medicine specialists, physiotherapists, and clinical psychologists.
Number of subjects: 3840
Study 32940745 — intervention group
Group type: COMPARATOR
Intervention: Single assessment by a pain specialist (Control).
Number of subjects: 3840
Study 32508201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral intervention
Number of subjects: 0
Study 32508201 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 0
Study 32517844 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined online and face-to-face dietary intervention focusing on self-compassion, goal-setting and self-monitoring
Number of subjects: 14
Study 33450422 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exposure to carbon monoxide (100-ppb increment)
Number of subjects: 398
Study 33450422 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exposure to nitrogen dioxide (10-ppb increment)
Number of subjects: 398
Study 33450422 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to significant levels of air pollution)
Number of subjects: 398
Study 33746023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (intravitreal anti-VEGF agents)
Number of subjects: 0
Study 33746023 — intervention group
Group type: COMPARATOR
Intervention: Real-world evidence (RWE) outcomes
Number of subjects: 0
Study 32780999 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin 250 mg loading dose followed by continuous infusion of 2000 mg per 24 hours
Number of subjects: 120
Study 32780999 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical saline infusion)
Number of subjects: 120
Study 32780999 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin
Number of subjects: 120
Study 32780999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35801003 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs) and H2 blockers
Number of subjects: 208188
Study 34836236 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Protein Supplementation (PP; 75 total g/d of powder providing 30 g/d protein, >9.2 g/d essential amino acids, 315 kcal/d)
Number of subjects: 47
Study 34836236 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-supplement group; CTL; n = 16 females, n = 8 males)
Number of subjects: 47
Study 34836236 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Protein Supplementation (PP)
Number of subjects: 47
Study 34591551 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSAAF prevention program
Number of subjects: 346
Study 34591551 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 346
Study 34435469 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 36
Study 34435469 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat and rasburicase
Number of subjects: 36
Study 34435469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32076569 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized temperature‐reduced dialysate protocol (dialysate temperature set between 0.5°C and 0.9°C below the patient’s predialysis body temperature, minimum 35.5°C)
Number of subjects: 15500
Study 32076569 — intervention group
Group type: COMPARATOR
Intervention: Standard‐temperature dialysate protocol (36.5°C)
Number of subjects: 15500
Study 36181618 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction-based surgery
Number of subjects: 150
Study 33368960 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140112 (LY) 100 mg
Number of subjects: 17
Study 33368960 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140112 (LY) 130 mg
Number of subjects: 17
Study 33368960 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140112 (LY) 5-75 mg
Number of subjects: 17
Study 33368960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 32389013 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI group
Number of subjects: 20
Study 32389013 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF group
Number of subjects: 20
Study 32389013 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between AMI and PAF groups
Number of subjects: 20
Study 32389013 — intervention group
Group type: COMPARATOR
Intervention: SAP group
Number of subjects: 20
Study 35132458 — intervention group
Group type: EXPERIMENTAL
Intervention: Neu‐BoNT/A
Number of subjects: 0
Study 32164785 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib dose reduction from 125 mg to 100 mg
Number of subjects: 311
Study 32164785 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib (125 mg)
Number of subjects: 311
Study 32164785 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib dose reduction
Number of subjects: 311
Study 35524006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 85
Study 35524006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 33273515 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaled equipment (smaller racket and a softer ball)
Number of subjects: 21
Study 33273515 — intervention group
Group type: COMPARATOR
Intervention: Full-sized equipment
Number of subjects: 21
Study 35272029 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids + 5ASA (4gr/day mesalamine)
Number of subjects: 149
Study 35272029 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids + 5ASA
Number of subjects: 149
Study 32326806 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 160
Study 32326806 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RA (liraglutide)
Number of subjects: 160
Study 32326806 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2i (empagliflozin)
Number of subjects: 160
Study 32326806 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RA + SGLT-2i (combination therapy)
Number of subjects: 160
Study 32326806 — intervention group
Group type: COMPARATOR
Intervention: Control (Insulin)
Number of subjects: 160
Study 35914255 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dietary sodium to less than 100 mmol
Number of subjects: 0
Study 35914255 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33978502 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 302
Study 32591250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum iron levels
Number of subjects: 643
Study 32591250 — intervention group
Group type: COMPARATOR
Intervention: Control group (high SI levels)
Number of subjects: 643
Study 35490936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU) and Methylprednisolone (40 mg)
Number of subjects: 501
Study 35490936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 34531021 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 60
Study 34531021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34531021 — intervention group
Group type: COMPARATOR
Intervention: No treatment (no-tablet months)
Number of subjects: 60
Study 34531021 — intervention group
Group type: COMPARATOR
Intervention: Statin vs Placebo
Number of subjects: 60
Study 34531021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo ratio
Number of subjects: 60
Study 34531021 — intervention group
Group type: COMPARATOR
Intervention: Stopping statin vs placebo
Number of subjects: 60
Study 33164896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 305
Study 33164896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 305
Study 33164896 — intervention group
Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 305
Study 32912727 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational module on cost-effective ordering
Number of subjects: 63